In today’s ACT Brief, we examine how predictive analytics are shaping portfolio decisions, how industry collaboration is ...

Angela Zubel, chief development officer, Debiopharm, explains how AI-enabled site selection, patient allocation, and real-time data monitoring can reduce costs, shorten timelines, and limit ...

In today’s ACT Brief, we examine how SCOPE 2026 reinforced the link between speed and strategy, how AI adoption is driving real-world efficiency gains, and how FDA’s evolving evidence standards could ...

In today’s ACT Brief, we examine how AI is enabling continuous trial monitoring and faster site decisions, how provider ...

Angela Zubel, chief development officer, Debiopharm, discusses why 2026 marks a shift from AI pilots to broader operational ...

Miriam Dervan, founder & CEO of mdgroup, discusses how patient-centered strategies rooted in empathy and advocacy engagement ...

Mike Wenger, chief innovation officer at CRIO, explains how AI can responsibly support data quality and monitoring with ...

In today’s ACT Brief, we examine how AI is shifting from pilot programs into daily development workflows, how a new adoption ...

Findings from the VA’s Diuretic Comparison Project show pragmatic trial designs can achieve strong provider participation when burden is minimized and patient care remains the primary focus.

In today’s ACT Brief, we examine new data on regional variation in clinical trial risk, why patient experience must move from ...

Holly Leslie, vice president of services at Ledger Run, discusses how persistent payment friction, increasing administrative ...

Using KRIs or SDM, sponsors can detect a variety of emerging risks, including inadequate adverse-event reporting, protocol ...